Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 2Phase 3 1Phase 1/2 1

Status

Terminated 4Completed 2

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Sarcoma 1Other hematologic neoplasm 1Genitourinary 1

Conditions

Multiple Myeloma 2Lymphoma 2Recurrence 1Prostatic Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Liposarcoma 1Leukemia 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Interventional × plitidepsin × Clear all
NCT01876043 2021-01-25

APLIPO

Institut Bergonié

Phase 2 Terminated
24 enrolled 10 charts
Sarcoma

Liposarcoma, Neoplasm Metastasis, Recurrence

NCT03117361 2020-12-02

Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide

PharmaMar

Phase 2 Terminated
10 enrolled 37 charts
Plasma cell

Multiple Myeloma

NCT00780975 2020-11-24

A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer

PharmaMar

Phase 2 Terminated
8 enrolled 9 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT03070964 2020-10-14

A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma

PharmaMar

Phase 2 Terminated
14 enrolled 21 charts
Lymphoid

Lymphoma

NCT00884286 2018-04-25

Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma

PharmaMar

Phase 2 Completed
67 enrolled 14 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT00229203 2009-12-24

A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma

PharmaMar

Phase 2 Completed
51 enrolled 10 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡